- Home
- APLT vs PASG Comparison
APLT vs PASG Comparison
Compare APLT & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLT
- PASG
- Stock Information
- Founded
- APLT 2016
- PASG 2017
- Country
- APLT United States
- PASG United States
- Employees
- APLT N/A
- PASG N/A
- Industry
- APLT Biotechnology: Pharmaceutical Preparations
- PASG Biotechnology: Pharmaceutical Preparations
- Sector
- APLT Health Care
- PASG Health Care
- Exchange
- APLT Nasdaq
- PASG Nasdaq
- Market Cap
- APLT 37.5M
- PASG 31.1M
- IPO Year
- APLT 2019
- PASG 2020
- Fundamental
- Price
- APLT $0.33
- PASG $0.33
- Analyst Decision
- APLT Buy
- PASG Strong Buy
- Analyst Count
- APLT 7
- PASG 3
- Target Price
- APLT $6.10
- PASG $7.67
- AVG Volume (30 Days)
- APLT 2.3M
- PASG 164.5K
- Earning Date
- APLT 04-14-2025
- PASG 05-13-2025
- Dividend Yield
- APLT N/A
- PASG N/A
- EPS Growth
- APLT N/A
- PASG N/A
- EPS
- APLT N/A
- PASG N/A
- Revenue
- APLT $455,000.00
- PASG N/A
- Revenue This Year
- APLT $3,031.87
- PASG N/A
- Revenue Next Year
- APLT $312.01
- PASG N/A
- P/E Ratio
- APLT N/A
- PASG N/A
- Revenue Growth
- APLT N/A
- PASG N/A
- 52 Week Low
- APLT $0.30
- PASG $0.30
- 52 Week High
- APLT $10.62
- PASG $1.64
- Technical
- Relative Strength Index (RSI)
- APLT 36.05
- PASG 39.03
- Support Level
- APLT $0.30
- PASG $0.30
- Resistance Level
- APLT $0.38
- PASG $0.41
- Average True Range (ATR)
- APLT 0.05
- PASG 0.06
- MACD
- APLT -0.00
- PASG 0.00
- Stochastic Oscillator
- APLT 17.19
- PASG 25.00
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
About PASG Passage Bio Inc.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.